Expert Opinion on Pharmacotherapy
Journal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | 3.4 | Q2 | 60.1% | 0.765 | Q2 | 75.8% |
| 2024 | 2.7 | Q2 | 53.8% | 0.672 | Q2 | 72.2% |
| 2023 | 2.5 | Q3 | 50.3% | 0.687 | Q2 | 75.1% |
| 2022 | 3.2 | Q3 | 57.0% | 0.702 | Q2 | 76.9% |
| 2021 | 4.1 | Q2 | 70.0% | 0.735 | Q2 | 78.9% |
| 2020 | — | — | 0.873 | Q2 | 82.1% | |
| 2019 | — | — | 0.742 | Q2 | 78.4% | |
| 2018 | — | — | 0.866 | Q2 | 80.6% | |
Impact history
Annual SJR and Impact Factor trend.
SJRIF
Journal record
eISSN
1465-6566
ISSN
1744-7666
region
Western Europe
coverage
1999-2026